QuantiPlasma Antibody MicroArray
Biomarker Discovery through Antibody Microarrays
The Randox - Biosystems QuantiPlasma array is a monoclonal antibody microarray designed for research and development purposes to assess the level of many unique proteins in human plasma. Using the QuantiPlasma array it is possible to directly assess the plasma proteome of normal and disease state plasma samples for the identification of novel biomarkers. Each kit contains 300 unique monoclonal antibodies that can be assessed simultaneously using the revolutionary Biochip Array Technology.
What are Antibody Microarrays?
Antibody Microarrays represent a first in the microarray field by offering the capacity to explore the human proteome using antibody binding elements with native human protein binding affinity and specificity. Each spot on the QuantiPlasma biochip microarray reports to a single human plasma protein. The option for further assessment is also available with Protein IDs or Cognate Expressed Protein Tag (CEPT) available for all antibodies. The combined attributes render QuantiPlasma as the ultimate biomarker discovery tool.
Why use QuantiPlasma Antibody Microarrays for Biomarker Discovery?
- Monoclonal antibodies raised against native human plasma proteins
- Devoid of antibodies with weak binding affinity and cross-reactivity as only high affinity antibodies are selected
- Small sample volumes accelerate binding kinetics and minimises assay interferences - only 5μL of neat sample required
- Rapid testing with results processed in less than three hours on the Evidence Investigator analyser
- No manual manipulation of results required with dedicated software for ease of patient profiling and result quantification
- Imprecision typically less than 10%
- No lengthy preparation steps required with a separate pre-labelled biotinylated plasma tracer (provided in the kit) and a single pre sample dilution
The QuantiPlasma Antibody Microarray will improve the precision, speed and rate of biomarker discovery for laboratories, research, proteomic, clinical, pharmaceutical, and diagnostic applications.
The array offers a revolutionary alternative to complex and costly proteomics approaches, thus bringing the protein biomarker discovery process to any laboratory.